Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

5Total
Early P 1 (2)
P 1 (1)
P 2 (1)
P 3 (1)

Trial Status

Active Not Recruiting2
Recruiting2
Unknown1
Not Yet Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials
NCT06824662Early Phase 1Active Not RecruitingPrimary

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

NCT03405792Phase 2Active Not Recruiting

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

NCT06773481Phase 1Recruiting

BC008-1A Injection for Recurrent CNS WHO G4 Glioma

NCT06883747Early Phase 1RecruitingPrimary

Clinical Trial of BMS-986504 in Recurrent GBM Patients

NCT06845020Not Yet Recruiting

CSF Proteomic Characterization of Glioblastomas

NCT03243461Phase 3UnknownPrimary

International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)

Showing all 6 trials

Research Network

Activity Timeline